MBX at a glance
MBX Biosciences, Inc. (MBX, SEC CIK 1776111) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding MBX Biosciences, Inc. (MBX) shares worth $537.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Hoerter Steven L. on November 10, 2026 of 4,893 shares at $54.82 per share.
- In the last 90 days, MBX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($288K) on Form 4, a net sale of $288K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$288K
- 13F holders
- 25 funds
- $537.7M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Clinical-stage biopharma developing novel precision peptide therapies for endocrine and metabolic disorders via proprietary PEP™ platform
- New emphasis on once-weekly canvuparatide for chronic hypoparathyroidism with positive Phase 2 data; Phase 3 trial to start Q3 2026
- Strategic focus broadened with obesity portfolio including MBX 4291, a potential once-monthly GLP-1/GIP co-agonist advancing through Phase 1 and planned multiple ascending doses study in 2026
- Notable metric: Phase 2 trial of canvuparatide enrolled 64 HP patients with 63% responder rate at 12 weeks vs 31% placebo (p=0.042)
- Unique to 2026 filing: First detailed presentation of canvuparatide’s programmable prodrug and fatty acylation dual technology enabling continuous, infusion-like peptide exposure with low peak-to-trough ratio
Risk Factors
- FDA regulatory risk: potential requirement for additional preclinical or clinical studies increasing costs and delaying approvals
- Geopolitical/macroeconomic risk: $373.7M cash runway into 2029 threatened by economic uncertainty and geopolitical tensions impacting operations
- Operational risk: reliance on third-party manufacturers for clinical and commercial supply with risk of inadequate supply or quality of product candidates
- Competition risk: facing competing technological and market developments that may reduce value of future product candidates
- Financial risk: accumulated deficit $224.5M with ongoing losses ($87.0M in 2025) and need for substantial financing to continue development and commercialization
Management Discussion & Analysis
- Net loss $87.0M in 2025 vs $61.9M in 2024; operating expenses rose $29.9M to $98.1M
- R&D expenses $79.2M (29.7% increase) driven by canvuparatide ($37.2M, up $15.6M) and MBX 4291 ($12.7M, up $1.9M); imapextide decreased $7.4M
- G&A expenses $18.9M up from $10.8M due to higher professional fees and personnel costs
- Cash, cash equivalents and marketable securities $373.7M at 12/31/25 vs $262.1M at 12/31/24; IPO net proceeds $170.5M, September 2025 Offering net proceeds $187.4M, and $87.1M raised via open market sales in early 2026
- Guidance: existing cash expected to fund operations into 2029; Phase 3 trial initiation of canvuparatide in Q3 2026; key risks include need for substantial new funding and clinical/regulatory uncertainties
AI summary of the MBX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors in the 2025 Annual Report
- Business, prospects, operating results and financial condition could suffer materially
- Common-stock trading price could decline, risking partial or total investment loss
- Additional risks currently unknown or deemed immaterial could adversely affect the business
Management Discussion & Analysis
- Product revenue $0, unchanged YoY, no approved products or sales
- Net loss $62.4M vs $21.6M YoY, operating margin not applicable
- R&D $32.0M vs $19.3M, canvuparatide largest program at $13.6M
- Cash, equivalents and securities $481.6M vs $373.7M; operating cash use $77.7M
- Outlook: funding projected into 2029, expenses rising with Phase 3 and obesity pipeline development
AI summary of the MBX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1 press release
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation signals refreshed investor messaging as of November 9, 2026
- Presentation may contain material pipeline, clinical, financing, or strategic updates
Item EX-99.1: Item EX-99.1
- Q3 net loss $62.4M, or $1.29 per share, versus $21.6M and $0.63 in Q3 2025
- R&D expense $32.0M, up from $19.3M, reflecting Phase 3 canvuparatide trial startup and obesity programs
Item EX-99.2: Item EX-99.2
- November 2026 presentation highlights $481.6M in cash, expected to fund operations into 2029
- Canvuparatide Phase 3 trial ongoing for hypoparathyroidism, with 26-week placebo-controlled treatment and 78-week open-label extension
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Peter Radovich appointed independent director effective October 20, 2026, expanding the Board to eight members
- Class I director term runs through the 2028 Annual Meeting, supporting near-term board continuity
Item 8.01: Other Events
- First patient dosed in pivotal Phase 3 oPTimize trial, advancing canvuparatide toward potential registration
- Global randomized trial targeting approximately 160 chronic hypoparathyroidism patients, with 26-week placebo-controlled treatment
Item 7.01: Regulation FD Disclosure
- First patient dosed in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide
- Trial targets adults with hypoparathyroidism, advancing MBX’s lead program into late-stage development
AI summaries of MBX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MBX
Don't miss the next MBX filing
- Alerts as it files. A push when MBX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MBX, by share count.
- Ask anything. An AI agent that reads every MBX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hoerter Steven L. | Sell | Nov 10, 2026 | 4,893 | $54.82 |
| Azoulay Salomon | Sell | Nov 4, 2026 | 373 | $53.96 |
| Radovich Peter | A | Oct 20, 2026 | 18,200 | - |
| Azoulay Salomon | Sell | Aug 4, 2026 | 370 | $65.77 |
| Smither John W | A | Aug 3, 2026 | 130,000 | - |
| Smither John W | A | Aug 3, 2026 | 28,000 | - |
| Hoerter Steven L. | A | Aug 3, 2026 | 331,000 | - |
| Hoerter Steven L. | A | Aug 3, 2026 | 71,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$35.3M | -$68.2M | -$98.1M |
| Net Income | - | -$61.9M | -$87.0M |
| Balance Sheet | |||
| Total Assets | $84.2M | $268.5M | $385.1M |
| Equity | -$72.5M | $257.4M | $369.2M |
| ROE | - | -24.1% | -23.6% |
| Per Share | |||
| EPS | $-31.96 | $-5.82 | $-2.38 |
| Cash Flow | |||
| Operating CF | -$32.0M | -$54.7M | -$79.9M |
| CapEx | $129K | $874K | $1.9M |
Source: XBRL data in MBX Biosciences, Inc. (MBX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MBX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $537.7M |
| Q2 2026 | 25 | $820.1M |
| Q1 2026 | 23 | $371.2M |
| Q4 2025 | 22 | $290.7M |
| Q3 2025 | 21 | $153.5M |
| Q2 2025 | 18 | $60.8M |
| Q1 2025 | 15 | $14.4M |
| Q4 2024 | 10 | $34.8M |
- BlackRock+149.8K (+5%)
- Invesco Ltd+92.0K (+182%)
- Franklin Resources+40.6K (+16%)
- Northern Trust+15.5K (+6%)
- Citigroup+5.7K (+23%)
- T. Rowe Price Group−193.2K (-24%)
- Prudential Financial−56.4K (-64%)
- D.E. Shaw & Co−55.5K (-30%)
- Vanguard Capital Management LLC−46.5K (-3%)
- Morgan Stanley−46.1K (-19%)
- Ameriprise Financial+107.6K
- Citadel Advisors LLC+7.6K
- Principal Financial Group+3.6K
- FMR LLC (Fidelity)−5.32M
- Millennium Management−226.2K
- Blackstone Group−5.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 159 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MBX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 5, 2026 | - | - | - |
| 4 | Oct 22, 2026 | - | - | - |
| 8-K | Oct 22, 2026 | - | Analysis | - |
| 8-K | Aug 27, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| SC 13G | Jul 29, 2026 | - | - | |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| SC 13G | Jun 24, 2026 | - | - | |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MBX SEC filings: frequently asked questions
Are MBX insiders buying or selling?
In the last 90 days, MBX Biosciences, Inc. (MBX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $288,361 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MBX stock?
As of September 30, 2026, the largest MBX Biosciences, Inc. (MBX) holders among the 13F filers tracked by SignalX were BlackRock ($203.6 million), Vanguard Capital Management LLC ($83.9 million), State Street Corp ($50.5 million), T. Rowe Price Group ($36.4 million), Goldman Sachs Group ($24.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in MBX's latest 10-K?
In the 10-K filed March 12, 2026, MBX Biosciences, Inc. (MBX) flagged: FDA regulatory risk: potential requirement for additional preclinical or clinical studies increasing costs and delaying approvals. Geopolitical/macroeconomic risk: $373.7M cash runway into 2029 threatened by economic uncertainty and geopolitical tensions impacting operations. (AI summary of the Risk Factors section.)
What did MBX report in its latest 8-K?
MBX Biosciences, Inc. (MBX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest MBX SEC filings?
MBX Biosciences, Inc. (MBX) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.
What is MBX's SEC CIK number?
MBX Biosciences, Inc. (MBX)'s SEC Central Index Key (CIK) is 1776111. EDGAR lists every MBX filing under that number.
Ask anything about MBX
The research agent reads MBX's filings, financials, insider trades and 13F holders, then answers with sources.